Thermo Fisher Scientific Inc. 10-Q Summary: Q1 2026
Business Context and Reporting Period
This summary covers the unaudited quarterly report (Form 10-Q) for Thermo Fisher Scientific Inc. for the three-month period ended March 28, 2026. The company operates in four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. It serves pharmaceutical, biotech, academic, government, industrial, and healthcare markets globally.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $11,005 million | $10,364 million |
| Operating Income (GAAP) | $1,863 million | $1,716 million |
| Net Income (GAAP) | $1,651 million | $1,507 million |
| Diluted EPS (GAAP) | $4.43 | $3.98 |
| Operating Cash Flow | $1,192 million | $723 million |
| Free Cash Flow (Non-GAAP) | $825 million | $373 million |
| Total Debt | $43,161 million | $39,384 million |
| Cash & Equivalents | $3,254 million | $9,852 million |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased 6% year-over-year. Organic revenue growth was 1%, driven by a 3% impact from acquisitions and 2% from currency translation.
- Profitability: GAAP operating income margin expanded to 16.9% from 16.6%. Adjusted operating income margin remained stable at 21.8% (down 0.1 percentage points).
- Acquisitions: The company acquired Clario Holdings, Inc. for approximately $9.1 billion (including debt settled) in March 2026, significantly impacting cash flow and debt levels. This acquisition added $3 billion to reported revenue growth.
- Divestiture: Agreed to sell its microbiology business (Specialty Diagnostics segment) for approximately $1.075 billion, expected to close in H2 2026.
- Capital Allocation: The company repurchased $3.0 billion of common stock and paid $162 million in dividends. Net debt increased due to financing the Clario acquisition and share buybacks.
Outlook, Risks, and Management Commentary
- Market Conditions: Pharma and biotech markets showed strong growth. Academic and government markets declined due to muted macro conditions in the U.S. and China. Diagnostics and healthcare markets also declined.
- Restructuring: Q1 2026 restructuring costs were $49 million, down from $98 million in Q1 2025. Management expects additional restructuring charges of approximately $290 million in 2026, primarily in the Laboratory Products and Biopharma Services segment.
- Tax Rate: The GAAP effective tax rate was 4.0%, significantly lower than the statutory rate due to $175 million in deferred tax benefits from domestication transactions. The adjusted tax rate was 10.5%. Management expects the 2026 GAAP effective tax rate to be between 9% and 11%.
- Liquidity: Cash balances decreased significantly due to the Clario acquisition. The company maintains a $5.0 billion revolving credit facility with no borrowings outstanding as of March 28, 2026.
- Risks: Key risks include macroeconomic conditions affecting academic/government spending, currency fluctuations, integration risks from the Clario acquisition, and potential impacts from tariffs.
Investor Verification Checklist
- Clario Integration: Verify the timeline and financial impact of integrating Clario Holdings, including the realization of synergies and the tax deductibility of goodwill (noted as non-deductible).
- Microbiology Divestiture: Monitor the closing status of the $1.075 billion sale of the microbiology business and its impact on the Specialty Diagnostics segment.
- Restructuring Costs: Track the execution of the anticipated $290 million in additional restructuring charges for 2026 and their impact on operating margins.
- Academic/Government Demand: Assess the sustainability of the decline in academic and government markets, particularly in the U.S. and China, and its effect on the Analytical Instruments segment.
- Debt Servicing: Review the impact of increased debt levels ($43.2 billion) on interest expense and liquidity, especially given the high interest rate environment.